TAK-755 Emerging Drug Insight

“TAK-755 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about TAK-755 for thrombocytopenia in the seven major markets. A detailed picture of the TAK-755 for thrombocytopenia in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the TAK-755 for thrombocytopenia. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TAK-755 market forecast analysis for thrombocytopenia in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in thrombocytopenia.

Drug Summary

TAK-755 (BAX930/SHP655) is a human recombinant ADAMTS13, the plasma metalloprotease that regulates the von Willebrand factor (VWF) multimers.

The drug provide an alternative to the current replacement of ADAMTS13 using large volumes of fresh frozen plasma that contain variable amounts of ADAMTS13 and typically require 2 h or more for the preparation and infusion. In contrast, BAX 930 can be quickly reconstituted and may thus be suitable for treatment in the patient’s home. ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats-13) cleaves VWF. This process is essential for hemostasis. Severe deficiency of plasma ADAMTS13 activity, most commonly resulting from autoantibodies against ADAMTS13, causes thrombotic thrombocytopenic purpura (TTP) (Baxalta, 2016).

Takeda is currently evaluating TAK-755 in Phase III clinical trial to treat congenital TTP and in Phase II for Immune TTP. The filing of congenital TTP is on-track in the US, whereas in Europe the company targets filing by 2023 and in Japan and China by 2024.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TAK-755 description, mechanism of action, dosage and administration, research and development activities in thrombocytopenia.
• Elaborated details on TAK-755 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TAK-755 research and development activities in thrombocytopenia across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TAK-755.
• The report contains forecasted sales of for thrombocytopenia till 2032.
• Comprehensive coverage of the late-stage emerging therapies for thrombocytopenia.
• The report also features the SWOT analysis with analyst views for TAK-755 in thrombocytopenia.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TAK-755 Analytical Perspective by DelveInsight

In-depth TAK-755 Market Assessment

This report provides a detailed market assessment of TAK-755 for thrombocytopenia in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

TAK-755 Clinical Assessment

The report provides the clinical trials information of TAK-755 for thrombocytopenia covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for thrombocytopenia is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TAK-755 dominance.
• Other emerging products for thrombocytopenia are expected to give tough market competition to TAK-755 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TAK-755 in thrombocytopenia.
• Our in-depth analysis of the forecasted sales data of TAK-755 from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TAK-755 in thrombocytopenia.

Key Questions

• What is the product type, route of administration and mechanism of action of TAK-755?
• What is the clinical trial status of the study related to TAK-755 in thrombocytopenia and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TAK-755 development?
• What are the key designations that have been granted to TAK-755 for thrombocytopenia?
• What is the forecasted market scenario of TAK-755 for thrombocytopenia?
• What are the forecasted sales of TAK-755 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to TAK-755 for thrombocytopenia?
• Which are the late-stage emerging therapies under development for the treatment of thrombocytopenia?